Table 5.

Facility AVF Use as a Function of Casemix and Other Facility Characteristics

Variable	β	P-value
Intercept	55.868	< 0.001
Percent Female	-0.135	< 0.001
Average Age	-0.149	0.001
Percent Caucasian	0.058	< 0.001
Percent Hispanic	0.039	< 0.001
Percent Diabetes as Primary Cause	0.087	0.001
Percent Hypertension as Primary Cause	0.005	0.8
Percent Glomerulonephritis as Primary Cause	0.144	< 0.001
Polycystic Kidney Disease as Primary Cause	-0.078	0.2
Percent PVD Co-morbidity	-0.086	0.005
Percent ASHD or IHD Co-morbidity	-0.005	0.8
Percent Hypertension Co-morbidity	-0.023	0.3
Percent Diabetes Co-morbidity	-0.019	0.4
Percent using AVF at Start of Maintenance HD	0.652	< 0.001
Facility HD patients	0.007	0.1
Large Dialysis Organization	0.760	0.03
F value	69.25	< 0.001
R2	0.202

Source: Centers for Medicare & Medicaid Services, Standard Information Medical System, End Stage Renal Disease Medical Evidence Report Medicare Entitlement and/or Patient Registration, Form CMS-2728, January 2007 – April 2010. Source for facility HD patients and LDO data: Centers for Medicare & Medicaid Services, Vascular Access Data Set as delivered by the Network Information Technology Support contractor to Fistula First Breakthrough Initiative contractor, January 2007 – April 2010.

AVF, arteriovenous fistula; Peripheral Vascular Disease (PVD); Atherosclerotic Heart Disease (ASHD); Ischemic Heart Disease (IHD); Hemodialysis (HD)